Feiba VH Related Published Studies
Well-designed clinical trials possibly related to Feiba VH (Anti-Inhibitor Coagulant Complex)
Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors - Phase I trial. [2011.04.28]
Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor. [2008.06]
Other research related to Feiba VH (Anti-Inhibitor Coagulant Complex)
Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. [2011.11.03]
Experience of four UK comprehensive care centres using FEIBA(R) for surgeries in patients with inhibitors. [2011.01]
Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors. [2010.03]
Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series. [2010.01]
FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations. [2010.01]
Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. [2009.07]
FEIBA in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre. [2009.05]
Factor eight inhibitor bypassing activity (FEIBA) for refractory bleeding in cardiac surgery: review of clinical outcomes. [2008.11]
Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues. [2008.01]
Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues. [2007.10.23]
Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. [2007.05]
Use of FEIBA for invasive or surgical procedures in patients with severe hemophilia A or B with inhibitors. [2007.04]
A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. [2007.01.15]
Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors. [2007]
A retrospective postlicensure survey of FEIBA efficacy and safety. [2006.07]
New approaches to using FEIBA in the treatment of inhibitor patients. [2006.06]
Surgery in patients with hemophilia and inhibitors: a review of the Norwegian experience with FEIBA. [2006.04]
Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience. [2004.09]
FEIBA safety profile in multiple modes of clinical and home-therapy application. [2004.09]
FEIBA: mode of action. [2004.09]
Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX. [2004.03]
Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. [2003.05]
Anti-inhibitor coagulant complex for the rescue therapy of acquired inhibitors to factor VIII: case report and review of the literature. [2002.09]
Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. [2002.03]
Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. [1997.06]
Myocardial infarction after FEIBA therapy in a hemophilia-B patient with a factor IX inhibitor. [1992.06]
Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. [1990.09]
Other possibly related research studies
Presurgical plasma exchange is ineffective in correcting amyloid associated factor X deficiency. [2004]
Inhibitors in haemophilia: clinical aspects. [2004.10]
Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. [2004.10]
Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. [2004.10]
Literature review of surgery management in inhibitor patients. [2004.09]
Cases of surgery in high-responder haemophilia patients. [2004.09]
Surgery in haemophilic patients with inhibitor: 20 years of experience. [2004.09]
Thrombin generation assay and other universal tests for monitoring haemophilia therapy. [2004.09]
Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. [2004.03]
A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone. [2003.11]
Dose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors. [2003.06]
West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data. [2003.08]
Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. [2003]
Acquired haemophilia due to factor VIII inhibitors in ovarian hyperstimulation syndrome: case report. [2003.03]
Evidence for the use of activated prothrombin complex concentrates (aPCCs) in the treatment of patients with haemophilia and inhibitors. [2002]
Postpartum acquired haemophilia: clinical recognition and management. [2001.05]
A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period. [2000.10]
Acquired haemophilia - a study of ten cases. [2000.03]
Treatment options for bleeding episodes in patients undergoing immune tolerance therapy. [1999.09]
Efficacy of viral clearance methods used in the manufacture of activated prothrombin complex concentrates: focus on AUTOPLEX T. [1999.09]
Complications associated with the treatment of haemophiliacs with inhibitors. [1999.09]
Management of haemophilia in patients with high-titre inhibitors: focus on the evolution of activated prothrombin complex concentrate AUTOPLEX T. [1999.09]
Manifestations of factor VIII inhibitor in the head and neck. [1999.11]
Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome. [1999]
Safety and efficacy of three arthroscopic procedures using Holmium: Yag laser in two high-responder haemophiliacs. [1999.07]
The impact of inhibitors on the cost of clotting factor replacement therapy in Haemophilia A in Canada. [1999.07]
Recommendations for the treatment of factor VIII inhibitors: from the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party. [1996.03]
[Spinal canal bleeding in hemophilia A] [1995.07]
Acute myocardial infarction complicating prothrombin complex concentrate therapy in an 8-year-old boy with hemophilia A and factor VIII inhibitor. [1993.11]
Hemarthrosis in patients with acquired factor VIII inhibitor. [1991.01]
Treatment of factor VIII inhibitors. [1990.06]
Seventeen years' experience with Autoplex/Autoplex T: evaluation of inpatients with severe haemophilia A and factor VIII inhibitors at a major haemophilia centre. [2000.09]
Viral safety of clotting factor concentrates. [1993]
A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor. [2006.09.21]
Recurrent intramural hematoma of the small intestine in a severe hemophilia A patient with a high titer of factor VIII inhibitor: a case report and review of the literature. [2006.08]
Current opinion on inhibitor treatment options. [2006.04]
Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors. [2006.01]
Management of factor VIII inhibitors. [2006]
Therapeutic decision-making in inhibitor patients. [2006.01]
Presentation and management of a stage Ia lung cancer patient with a paraneoplastic factor VIII inhibitor. [2006.01]
Anasarca improved by extracorporeal ultrafiltration through an internal shunt in a case of severe haemophilia B with inhibitor and steroid-resistant nephrotic syndrome. [2006.01]
Short-term oral corticosteroid therapy for acute haemarthrosis in haemophilia patients with high-titre inhibitors. [2007.01]
Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. [2005.09]
Successful self-infusion of activated prothrombin complex concentrate for prophylaxis in a child with a factor VIII inhibitor. [2007.02]
A case of acute upper and lower airway obstruction due to retropharyngeal haemorrhage secondary to acquired haemophilia A. [2007.06]
Cyclosporin A can achieve immune tolerance in a patient with severe haemophilia B and refractory inhibitors. [2007.01]
Single 270 mug kg(-1)-dose rFVIIa vs. standard 90 mug kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. [2007.12.10]
Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review. [2007.09]
Value added: increasing the power to assess treatment outcome in joint haemorrhages. [2008.03]
Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. [2008.03]
From theory to practice: applying current clinical knowledge and treatment strategies to the care of hemophilia a patients with inhibitors. [2008.02]
VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice. [2007.12]
Inhibitors in haemophilia A: current management and open issues. [2007.12]
Some recent developments regarding arthropathy and inhibitors in haemophilia. [2008.03]
Orthopaedic surgery for inhibitor patients: a series of 27 procedures (25 patients). [2007.09]
Case report: induction of immune tolerance to factor VIII inhibitor after a major operation. [2007.06]
Acquired hemophilia: a case report. [2008.04]
Acquired deficiency of vitamin K-dependent clotting factors due to brodifacoum ingestion. [2008.04]
Management of haemophilic arthropathy. [2008.07]
Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations. [2009.01]
Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors? [2008.11]
Prevention of arthropathy in haemophilia - intensive on-demand treatment, UK perspective. [2008.11]
Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate. [2009.01]
Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care. [2009.01]
Diagnosis and treatment of congenital hemophilia with inhibitors a Latin American perspective. [2008]
The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents. [2009.04]
Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. [2010.08.04]
Prophylaxis in haemophilia with inhibitors: update from international experience. [2010.03]
Management of hemophilia in patients with inhibitors: the perspective from developing countries. [2009.11]
Interlaboratory variation in factor VIII:C inhibitor assay results is sufficient to influence patient management: data from the UK national quality external assessment scheme for blood coagulation. [2009.11]
Inhibitors in hemophilia A: advances in elucidation of inhibitory mechanisms and in inhibitor management with bypassing agents. [2009.11]
Successful major and minor surgery using factor VIII inhibitor bypassing activity in patients with haemophilia A and inhibitors. [2009.11]
|
